Enoxaparin prevents progression of Stages I and II osteonecrosis of the hip

Clinical Orthopaedics and Related Research

Volumn 435, Issue , 2005, Pages 164-170

  Glueck, Charles J ^a,c   Freiberg, Richard A ^b   Sieve, Luann ^a   Wang, Ping ^a  

^a JEWISH HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Cholesterol Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ENOXAPARIN;

ADULT; ANEMIA; ARTICLE; BLEEDING; BONE NECROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FIBRINOLYSIS; FOLLOW UP; HIP DISEASE; HIP RADIOGRAPHY; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SINGLE BLIND PROCEDURE; SURVIVAL; THROMBOCYTOPENIA; THROMBOPHILIA; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME;

EID: 20444365449     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000157539.67567.03     Document Type: Article

References (43)

1. Arlet J, Ficat P: Diagnosis of primary femur head osteonecrosis at stage 1 (preradiologic stage). Rev Chir Orthop Reparatrice Appar Mot 54:637-648, 1968.
2. Assouline-Dayan Y, Chang C, Greenspan A, et al: Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32:94-124, 2002.
3. Balasa VV, Gruppo RA, Glueck CJ, et al: The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults. Thromb Haemost 81:739-744, 1999.
4. Balasa VV, Gruppo RA, Glueck CJ, et al: Legg-Calve-Perthes disease and thrombophilia. J Bone Joint Surg 86A:2642-2647, 2004.
5. Boss JH, Misselevich I: Osteonecrosis of the femoral head of laboratory animals: The lessons learned from a comparative study of osteonecrosis in man and experimental animals. Vet Pathol 40:345-354, 2003.
6. Coogan PG, Urbaniak JR: Multicenter experience with free vascularized fibular grafts for osteonecrosis of the femoral head. In Urbaniak JR, Jones Jr JP (eds). Osteonecrosis: Etiology, Diagnosis, and Treatment. Rosemont, IL, American Academy of Orthopaedic Surgeons 327-352, 1997.
7. Eldridge JC, Dilley A, Austin H, et al: The role of protein C, protein S, and resistance to activated protein C in Legg-Perthes disease. Pediatrics 107:1329-1334, 2001.
8. Garino JP, Steinberg ME: Total hip arthroplasty in patients with avascular necrosis of the femoral head: A 2- to 10-year follow-up. Clin Orthop 334:108-115, 1997.
9. Glueck CJ, Fontaine RN, Gruppo R, et al: The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop 366:133-146, 1999.
10. Glueck CJ, Freiberg RA, Fontaine RN, Sieve-Smith L, Wang P: Anticoagulant therapy for osteonecrosis associated with heritable hypofibrinolysis and thrombophilia. Expert Opin Investig Drugs 10:1309-1316, 2001.
11. Glueck CJ, Freiberg RA, Glueck HI, et al: Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol. Am J Hematol 48:213-220, 1995.
12. Glueck CJ, Freiberg RA, Wang P: Role of thrombosis in osteonecrosis. Curr Hematol Rep 2:417-422, 2003.
13. Glueck CJ, Iyengar S, Goldenberg N, Smith LS, Wang P: Idiopathic intracranial hypertension: Associations with coagulation disorders and polycystic-ovary syndrome. J Lab Clin Med 142:35-45, 2003.
14. Hoffman S, Mazieres B: Osteonecrosis: Natural course and conservative therapy. Orthopade 29:403-410, 2000.
15. Hresko MT, McDougall PA, Gorlin JB, et al: Prospective reevaluation of the association between thrombotic diathesis and Legg-Perthes disease. J Bone Joint Surg 84A:1613-1618, 2002.
16. Hungerford DS, Mont MA: The role of core decompression of osteonecrosis of the femoral head. In Urbaniak JR, Jones Jr JP (eds). Osteonecrosis: Etiology, Diagnosis, and Treatment. Rosemont, IL. American Academy of Orthopaedic Surgeons 287-292, 1997.
17. Jones Jr JP: Risk factors potentially activating intravascular coagulation and causing nontraumatic osteonecrosis. In Urbaniak JR, Jones Jr JP (eds). Osteonecrosis: Etiology, Diagnosis, and Treatment. Rosemont, IL, American Academy of Orthopaedic Surgeons 89-97, 1997.
18. Jones LC, Mont MA, Le TB, et al: Procoagulants and osteonecrosis. J Rheumatol 30:783-791, 2003.
19. Kearon C, Gent M, Hirsh J, et al: A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340:901-907. 1999.
20. Koo KH, Kim R, Cho SH, et al: Angiography, scintigraphy, intraosseous pressure, and histologic findings in high-risk osteonecrotic femoral heads with negative magnetic resonance images. Clin Orthop 308:127-138, 1994.
21. Koo KH, Kim R, Ko GH, et al: Preventing collapse in early osteonecrosis of the femoral head: A randomized clinical trial of core decompression. J Bone Joint Surg 77B:870-874, 1995.
22. Laroche M: Intraosseous circulation from physiology to disease. Joint Bone Spine 69:262-269, 2002.
23. Lieberman JR: Core decompression for osteonecrosis of the hip. Clin Orthop 418:29-33, 2004.
24. Liu SL, Ho TC: The role of venous hypertension in the pathogenesis of Legg-Perthes disease: A clinical and experimental study. J Bone Joint Surg 73A: 194-200, 1991.
25. Martin JL, Fry ET, Sanderink GJ, et al: Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 61:163-170, 2004.
26. McNicholas MJ, Brooksbank AJ, Walker CM: Observer agreement analysis of MRI grading of knee osteoarthritis. J R Coll Surg Edinb 44:31-33, 1999.
27. Mont MA, Glueck CJ, Pacheco IH, et al: Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 24:654-662, 1997.
28. National Center for Health Statistics: Division of Health Examination Statistics: The Third National Health and Nutrition Evaluation Survey (NHANES III), 1988-94, Series 11, No 11a (Knee osteoarthritis X-ray data and documentation) data release. Hyattsville, MD, Centers for Disease Control and Prevention, National Center for Health Statistics, http://www.cdc.gov/nchs/ about/major/mhanco/nh3data.html. Accessed October, 2001.
29. Norman D, Miller Y, Sabo E, et al: The effects of Enoxaparin on the reparative processes in experimental osteonecrosis of the femoral head of the rat. APMIS 110:221-228, 2002.
30. Norman D, Reis D, Zinman C, Misselevich I, Boss JH: Vascular deprivation-induced necrosis of the femoral head of the rat: An experimental model of avascular osteonecrosis in the skeletally immature individual or Legg-Perthes disease. Int J Exp Pathol 79:173-181, 1998.
31. Research Committee of the British Thoracic Society: Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 340:873-876, 1992.
32. Ritter MA, Helphinstine J, Keating EM, Paris PM, Meding JB: Total hip arthroplasty in patients with osteonecrosis: The effect of cement techniques. Clin Orthop 338:94-99, 1997.
33. Robinson Jr HJ: Success of core decompression in the management of early stages of avascular necrosis: A four year prospective study. Proceedings of the American Academy of Orthopaedic Surgeons 59th Annual Meeting, Washington, DC. Park Ridge, IL, American Academy of Orthopaedic Surgeons 177, 1992. Abstract.
34. Robinson Jr HJ, Hartleben PD, Lund G, Schreiman J: Evaluation of magnetic resonance imaging in the diagnosis of osteonecrosis of the femoral head: Accuracy compared with radiographs, core biopsy, and intraosseous pressure measurements. J Bone Joint Surg 71A:650-663, 1999.
35. Schulman S: Oral anticoagulation in venous thromboembolism: Decisions based on more than mere feelings. J Intern Med 245:399-403, 1999.
36. Schulman S, Rhedin AS, Lindmarker P, et al: A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism: Duration of anticoagulation trial study group. N Engl J Med 332:1661-1665, 1995.
37. Steinberg MA, Larcom PG, Stafford BB, et al: Treatment of osteonecrosis of the femoral head by core decompression, bone grafting, and electrical stimulation. In Urbaniak JR, Jones Jr JP (eds). Osteonecrosis: Etiology, Diagnosis, and Treatment. Rosemont, IL, American Academy of Orthopaedic Surgeons 293-299, 1997.
38. Stulberg BN, Davis AW, Bauer TW, Levine M, Easley K: Osteonecrosis of the femoral head: A prospective randomized treatment protocol. Clin Orthop 268:140-151, 1991.
39. Stulberg BN, Singer R, Goldner J, Stulberg J: Uncemented total hip arthroplasty in osteonecrosis: A 2- to 10-year evaluation. Clin Orthop 334:116-123, 1997.
40. Szepesi K, Posan E, Harsfalvi J, et al: The most severe forms of Perthes' disease associated with the homozygous Factor V Leiden mutation. J Bone Joint Surg 868:426-429, 2004.
41. Thaler HW, Roller RE, Greiner N, Sim E: Korninger: Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery. J Trauma 51:518-521, 2001.
42. Yasungay Y, Ikuta Y, Omoto O, et al: Transtrochanteric rotational osteotomy for osteonecrosis of the femoral head with preoperative superselective angiography. Arch Orthop Trauma Surg 120:437-440, 2000.
43. Zalavras C, Dailiana Z, Elisaf M, et al: Potential aetiological factors concerning development of osteonecrosis of the femoral head. Eur J Clin Invest 30:215-221, 2000.